Evidence map›Paper›PMID 37337052›Full record

ArticleProstate cancer and prostatic diseases2024

Correction to: ExoDx prostate test as a predictor of outcomes of high-grade prostate cancer - an interim analysis.

Ronald Tutrone, Ben Lowentritt, Brian Neuman, Michael J Donovan, Elliot Hallmark, T Jeffrey Cole, Yiyuan Yao, Claire Biesecker, Sonia Kumar, Vinita Verma and 3 more

Open access · hybridAbstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Prostate cancer and prostatic diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Ronald TutroneChesapeake Urology Research Associates, Baltimore, MD, USA. rtutrone@uniteduro.com.ORCID http://orcid.org/0000-0001-6705-778X
Ben LowentrittChesapeake Urology Research Associates, Baltimore, MD, USA.
Brian NeumanChesapeake Urology Research Associates, Baltimore, MD, USA.
Michael J DonovanIcahn School of Medicine at Mt. Sinai, New York City, NY, USA.ORCID http://orcid.org/0000-0003-0772-598X
Elliot HallmarkExosome Diagnostics, a Bio-Techne Brand, Waltham, MA, USA.
T Jeffrey ColeExosome Diagnostics, a Bio-Techne Brand, Waltham, MA, USA.
Yiyuan YaoExosome Diagnostics, a Bio-Techne Brand, Waltham, MA, USA.
Claire BieseckerChesapeake Urology Research Associates, Baltimore, MD, USA.
Sonia KumarExosome Diagnostics, a Bio-Techne Brand, Waltham, MA, USA.
Vinita VermaExosome Diagnostics, a Bio-Techne Brand, Waltham, MA, USA.
Grannum R SantExosome Diagnostics, a Bio-Techne Brand, Waltham, MA, USA.
Jason AlterExosome Diagnostics, a Bio-Techne Brand, Waltham, MA, USA.
Johan SkogExosome Diagnostics, a Bio-Techne Brand, Waltham, MA, USA.
Exosome Diagnostics (United States) · USChesapeake Urology Associates · USIcahn School of Medicine at Mount Sinai · USTufts University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID37337052
PMCPMC10876471
OpenAlexW4381165821

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.